POINT Biopharma Global Inc.: directors' dealings · United States · SEC (Form 4)

About POINT Biopharma Global Inc.

POINT Biopharma Global Inc. was a U.S.-listed biopharmaceutical company formerly traded on the NASDAQ under the ticker PNT before being acquired in late 2023. For international investors, POINT was best understood as a radiopharmaceutical specialist: a company operating at the intersection of oncology, nuclear medicine, and isotope-based drug development. It was founded to build a modern platform for radioligand discovery, clinical development, and manufacturing, with the goal of bringing targeted cancer therapies to market. The company’s core business centered on an integrated radiopharmaceutical platform. POINT combined internal R&D capabilities with manufacturing infrastructure and access to critical isotopes such as lutetium-177 and actinium-225. Its main pipeline assets were PNT2002, a PSMA-targeted radioligand therapy for prostate cancer, and PNT2003, aimed at neuroendocrine tumors. In addition, POINT was developing earlier-stage next-generation programs to broaden its pipeline beyond the lead assets. This made the company a focused, high-science biotech with a concentrated portfolio and a strong dependence on clinical execution. From a competitive standpoint, POINT operated in a promising but demanding niche. Success in radiopharmaceuticals depends not only on clinical data, but also on supply-chain control, isotope availability, manufacturing quality, regulatory execution, and the ability to scale production. POINT highlighted its in-house manufacturing base in Indianapolis, Indiana, as a strategic advantage for clinical supply and future commercialization. SEC filings also pointed to operational ties in South San Francisco, California, underscoring a footprint across key U.S. biotech hubs. The company also built collaborations designed to support development and commercialization efforts in North America and abroad. A major recent milestone was the completed acquisition of POINT by Eli Lilly in December 2023, which effectively ended POINT’s life as an independent public company. That transaction is important in two ways: it validated the strategic value of POINT’s radiopharmaceutical platform, and it illustrates how premium oncology assets can become acquisition targets for larger pharma groups seeking radioligand capabilities. Prior to the acquisition, POINT reported positive topline results from the Phase 3 SPLASH trial of ^177Lu-PNT2002 in metastatic castration-resistant prostate cancer, a key clinical de-risking event for the lead program. For investors in France, Belgium, and Switzerland, POINT Biopharma is a useful case study of a U.S.-based specialty biotech that built value through a narrow but differentiated oncology franchise. It was a United States company listed on NASDAQ, and its story was defined by targeted innovation, clinical progress, and eventual strategic absorption by a larger pharmaceutical platform.